Acrivon Therapeutics, Inc.
ACRV evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $85.7M
- Lead Asset:
- ACR-2316 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ACRV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACRV
Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biotechnology company developing precision medicines using its proprietary Generative Phosphoproteomics AP3 platform, with a pipeline including a Phase 2b registrational-intent CHK1/2 inhibitor (ACR-368) and a Phase 1/2 dual WEE1/PKMYT1 inhibitor (ACR-2316).
Key risk: Pre-revenue cash burn
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials for Acrivon Therapeutics, Inc..
Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biotechnology company developing precision medicines using its proprietary Generative Phosphoproteomics AP3 platform, with a pipeline including a Phase 2b registrational-intent CHK1/2 inhibitor (ACR-368) and a Phase 1/2 dual WEE1/PKMYT1 inhibitor (ACR-2316).
- Cash & equivalents of $41.4M as of 2026-06-30 [sec].
- Net income of -$18.0M as of 2026-06-30 [sec].
- Shareholders' equity of $86.7M as of 2026-06-30 [sec].
- Lead candidate ACR-368 (prexasertib) is a selective CHK1/CHK2 inhibitor in a Phase 2b registrational-intent trial for endometrial adenocarcinoma [pipeline].
- ACR-2316, a potential first-in-class dual WEE1/PKMYT1 inhibitor, is in Phase 1/2 for advanced solid tumors and has shown early partial responses across multiple AP3-predicted tumor types [pipeline][news·2026-07-21].
What works
- Proprietary AP3 platform enables rational drug design and predictive clinical development, potentially improving therapeutic index and single-agent activity [news·2026-09-02][news·2026-07-21].
- ACR-368 has Orphan Drug designation and is in a registrational-intent Phase 2b study, indicating a clear path to potential registration [pipeline].
- ACR-2316 has demonstrated early clinical responses, including partial responses, across multiple AP3-predicted tumor types, supporting platform utility [news·2026-07-21].
- Preclinical data show synergy of ACR-368 with Topo 1 inhibitor payloads (common in ADCs) and of ACR-2316 with anti-PD-L1 checkpoint inhibition, suggesting combination potential [news·2026-03-18].
What to weigh
- The company reported a net loss of $18.0M for the period ending 2026-06-30, indicating ongoing cash burn [sec].
- ACR-368 faces a competitive landscape with at least four other Phase 2 programs in endometrial adenocarcinoma, including from M.D. Anderson, Daiichi Sankyo, and Arvinas [pipeline].
- ACR-6840 (CDK11 inhibitor for AML) competes in a crowded space with 49 other Phase 2 programs, raising differentiation challenges [pipeline].
- The company is pre-revenue and dependent on pipeline success; no approved products or disclosed partnership revenues are noted in the provided data.
From the filings
Quoted directly from source documents.
ACR-368 is a selective CHK1/CHK2 inhibitor in Phase 2 for endometrial adenocarcinoma
“Pipeline Candidate: ACR-368 Generic Name: prexasertib Indication: Endometrial Adenocarcinoma Phase: Phase 2 Mechanism of Action: Selective CHK1 and CHK2 inhibitor”
ACR-2316 is a dual WEE1/PKMYT1 inhibitor in Phase 1/2 with early partial responses
“Early clinical responses, including partial responses (PRs) across multiple AP3-predicted tumor types, underscore how AP3-guided drug design translates into differentiated anti-tumor activity”
News · July 21, 2026
Catalyst timeline
- 2022-08-29 · Phase 2 start for ACR-368 in endometrial cancer — Initiation of the registrational-intent Phase 2 study for the lead candidate.
- 2024-10-08 · Phase 1/2 start for ACR-2316 in advanced solid tumors — First patient dosed in the Phase 1/2 study of the dual WEE1/PKMYT1 inhibitor.
Risks & what to watch (4)›
Key risks
- Pre-revenue cash burn — Net loss of $18.0M in the period ending 2026-06-30 with $41.4M cash; runway depends on pipeline milestones [sec].
- ACR-368 competitive pressure — At least four other Phase 2 programs in endometrial adenocarcinoma, including from major institutions and pharma [pipeline].
- Crowded AML space for ACR-6840 — 49 competitors in Phase 2 for AML, making differentiation and market entry challenging [pipeline].
- Dependence on platform validation — No approved products; clinical success of AP3-guided candidates is unproven at registrational level [news·2026-09-02].
What to watch
- Interim data from the ACR-368 Phase 2b registrational-intent trial, discussed at ESGO in February 2026 [news·2026-02-27].
- Further clinical updates on ACR-2316 from ongoing Phase 1/2 study, including expansion cohorts [pipeline][news·2026-07-21].
- Presentations at upcoming conferences (e.g., Cantor Global Healthcare Conference in September 2026) for platform and pipeline updates [news·2026-09-02].
- Financial runway and potential partnering or financing events given the net loss and cash position [sec].
Sources: Catalysts · Competitor trials · News · Pipeline · Generated October 4, 2026 · How we verify sources →
Run Acrivon Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Acrivon Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.14 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
0 buys · 8 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 12.5%
- Days to cover
- 3.9
- Shares short
- 2,388,157
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACRV short interestGovernance
Frequently asked questions
What is the AI investment thesis for Acrivon Therapeutics, Inc.?
Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biotechnology company developing precision medicines using its proprietary Generative Phosphoproteomics AP3 platform, with a pipeline including a Phase 2b registrational-intent CHK1/2 inhibitor (ACR-368) and a Phase 1/2 dual WEE1/PKMYT1 inhibitor (ACR-2316).
What is Acrivon Therapeutics, Inc.'s lead drug candidate?
Acrivon Therapeutics, Inc.'s most advanced tracked candidate is ACR-2316 (Phase 2) for Specific Advanced Solid Tumors.
Who is the CEO of Acrivon Therapeutics, Inc.?
Dr. Peter Blume-Jensen M.D., Ph.D. is the chief executive officer of Acrivon Therapeutics, Inc. (ACRV).
Where is Acrivon Therapeutics, Inc. headquartered?
Acrivon Therapeutics, Inc. (ACRV) is headquartered in Watertown, MA, United States.
What therapeutic areas does Acrivon Therapeutics, Inc. focus on?
Acrivon Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.